Advertisement

Search Results

Advertisement



Your search for The matches 34665 pages

Showing 23001 - 23050


head and neck cancer

Takeshi Kodaira, MD, PhD, on Glottic Cancer: Results of a Japan Clinical Oncology Group Study

Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)

issues in oncology

Louis Harrison, MD, on Radiation Oncology and the Future of Health Care

Louis B. Harrison, MD, of the Moffitt Cancer Center, discusses radiation oncology in the context of personalized medicine, multidisciplinary care, new technology and applications, and the mandate to contain costs.

issues in oncology

Lia M. Halasz, MD, on Disparities in Radiotherapy Delivery 126

Lia M. Halasz, MD, of the University of Washington Seattle Cancer Care Alliance, summarizes a session on the uneven delivery of radiotherapy in the United States and around the world. (Scientific Session 10)

kidney cancer
lung cancer
skin cancer

Combining AM0010 and Pembrolizumab Produced Antitumor Activity in Patients With Advanced Solid Tumors

A multibasket phase Ib study evaluating the clinical activity, tolerability, and antitumor activity of the cytokine-based immunotherapy AM0010 alone or in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) has found that in monotherapy, objective responses to AM0010 were ...

issues in oncology

Howard M. Sandler, MD, on RTOG’s Past and NRG’s Future 126

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)

prostate cancer

Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity 126

Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)

Brian Kavanagh, MD, MPH: Looking Ahead With ASTRO’s President-Elect

Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.

Bruce D. Minsky, MD's, Meeting Highlights: An Expert Perspective

Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.

breast cancer

Douglas W. Arthur, MD, on Breast-Preserving Surgery: Results From NRG Oncology/RTOG 1014 126

Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial breast reirradiation for in-breast recurrence. (Abstract LBA-10)

hematologic malignancies
leukemia

Improved Event-Free Survival With Addition of Rituximab to Chemotherapy in B-Lineage Adult ALL

In the phase III GRAALL-2005 trial reported in The New England Journal of Medicine, Maury et al found that the addition of rituximab (Rituxan) to standard chemotherapy resulted in improved event-free survival in adult patients with B-lineage acute lymphoblastic leukemia (ALL). Study Details In...

breast cancer

Effect of G-CSF Prophylaxis With Chemotherapy for Breast Cancer on Neutropenia-Related Hospitalization

In an analysis of commercial U.S. health plan data reported in the Journal of Clinical Oncology, Agiro et al found that granulocyte colony-stimulating factor (G-CSF) primary prophylaxis was associated with a “low-to-modest’’ benefit in preventing neutropenia-related...

colorectal cancer

Does Colonoscopy Screening in Older Adults Prevent Colorectal Cancer?

A large population-based observational study by García-Albéniz et al evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found the test reaped only a modest benefit in preventing colorectal...

head and neck cancer

Addition of CHK1 Inhibitor Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy

Combining a new targeted drug that blocks one of cancer’s escape routes could boost the effectiveness of combined chemoradiotherapy for head and neck cancers and stop cells becoming resistant to treatment. Researchers at The Institute of Cancer Research, London (ICR), and The Royal Marsden...

prostate cancer

Blood Biomarkers in Abiraterone- or Enzalutamide-Resistant Prostate Cancer Tumor Cells 

While searching for a noninvasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies. In a study published by Gupta et al in Clinical Cancer Research, a team...

breast cancer

10-Year Risk of Invasive Breast Cancer After Diagnosis of Atypical Ductal Hyperplasia by Needle Biopsy

The cumulative estimated risk of invasive breast cancer at 10 years after diagnosis of atypical ductal hyperplasia by core-needle biopsy was approximately 5%, according to a study reported by Menes et al in JAMA Oncology. The 10-year risk was 6.7% with atypical ductal hyperplasia diagnosed by...

pancreatic cancer

Analysis Indicates Survival Advantage With Neoadjuvant Therapy in Resectable Pancreatic Cancer

In a propensity score–matched analysis of National Cancer Database data reported in the Journal of Clinical Oncology, Mokdad et al found that neoadjuvant therapy followed by resection was associated with a survival benefit vs upfront resection. Study Details The analysis included adults...

prostate cancer

Large Study Finds No Link Between Vasectomy and Prostate Cancer Risk

In a new study, men who underwent vasectomy did not have an increased risk of prostate cancer, nor were they more likely to die from prostate cancer than men who did not receive this procedure. According to the researchers, this is the largest prospective study of vasectomy and fatal prostate...

Saul J. Sharkis, PhD, Stem Cell Researcher, Dies

Saul J. Sharkis, PhD, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died on September 4. He was 72. Dr. Sharkis was Professor of Oncology at the Johns Hopkins University School of Medicine and a faculty...

Nobel Laureate Roger Y. Tsien, PhD, Dies

In 2008, Roger Y. Tsien, PhD, shared the Nobel Prize in chemistry with Drs. Osamu Shimomura and Martin Chalfie for helping turn green fluorescent protein from a jellyfish into a research tool that could tag cancer cells or track the advance of Alzheimer’s disease. “Our work is often described as...

skin cancer

Study Confirms Benefit of Cobimetinib Plus Vemurafenib in Advanced BRAF V600–Mutant Melanoma

As reported by Ascierto et al in The Lancet Oncology, longer-term follow-up in the pivotal phase III coBRIM trial confirmed the benefit of adding cobimetinib to vemurafenib (Zelboraf) in first-line treatment of BRAF V600–mutant unresectable stage IIIC or IV melanoma. Grant A. McArthur, FRACP, of...

skin cancer

Combining Ipilimumab With Radiotherapy in Advanced Melanoma

The immunotherapy ipilimumab (Yervoy) has revolutionized the treatment of malignant melanoma and resulted in durable responses in 20% to 25% of patients with the cancer. ­Sebastian Theurich, MD, of the Center for Integrated Oncology at the University Hospital of Cologne in Germany, and colleagues...

symptom management

Olanzapine Combination Reduces Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

According to a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic...

multiple myeloma

Updated Outcomes, Impact of Age in Multiple Myeloma

Updated Outcomes, Impact of Age in Multiple Myeloma As reported by Hulin et al in the Journal of Clinical Oncology, the updated findings in the phase III FIRST trial continue to show improved progression-free and overall survival with continuous lenalidomide (Revlimid) plus low-dose dexamethasone...

2016-2017 Oncology Meetings

OCTOBER International Cancer Imaging Society Meeting and 16th Annual Teaching CourseOctober 3-5 • Glasgow, ScotlandFor more information:http://www.icimagingsociety.org.uk/index.cfm?task=meetings 9th International Workshop on Waldenstrom’s Macroglobulinemia & Symposia on Multiple MyelomaOctober...

The Anesthesia Era 1845–1875 Carte de Visite, London, circa 1858

For over 2,500 years, bloodletting was the backbone of medical therapy. To date, it is the longest-running therapeutic tradition known. First practiced in ancient Egypt, its use spread throughout Western civilization. The therapy was still performed in Southern rural America until the 1910s. One...

Emily L. Sedgwick, MD, Receives Ben and Margaret Love Foundation Bobby Alford Award for Academic Clinical Professionalism

Emily L. Sedgwick, MD, Associate Professor of Breast Imaging in the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center, has been named the 2016 recipient of the Ben and Margaret Love Foundation Bobby Alford Award for...

kidney cancer
breast cancer

I’ve Survived Cancer for Over 71 Years

Even though I was just 3 years old when my symptoms first appeared, the memory is still fresh in my mind to this day, 71 years later. I had just come home from a friend’s birthday party and was sitting on the front patio steps immobilized by severe stomach pain. My parents said I was feeling ill...

Michael Maitland, MD, PhD, Named Director of Therapeutics for the Inova Center for Personalized Health

Inova Health System is pleased to welcome Michael Maitland, MD, PhD, where he will serve as the new Director of Therapeutics for the Inova Center for Personalized Health and as Associate Director of Cancer Therapeutics for the Inova Schar Cancer Institute.  Dr. Maitland comes to Inova from the...

gynecologic cancers

An Ovarian Cancer Expert’s Guide Offers Insight, Wisdom, and Hope

There have been numerous books explicating the information a physician or patient needs to know about our current clinical state in the diagnosis and treatment of ovarian cancer. Many of them are good, but rare is a well-written book in the cancer genre that offers solid scientific hope exceeding ...

Cancer Moonshot Blue Ribbon Panel Recommends 10 Ways to Speed Cancer Advances

Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s...

issues in oncology
genomics/genetics

Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients

The Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group has received federal approval to add a quality-of-life research study, Communication and Education in Tumor Profiling (EAQ152), or COMET, to the NCI-MATCH (EAY131) trial, which is ...

2016 Lasker Awards Honor Scientists for Basic and Clinical Medical Research, Special Achievement

The Albert and Mary Lasker Foundation has announced the winners of the 2016 Lasker Awards for medical science: William G. ­Kaelin, MD; ­Peter J. Ratcliffe, MD, FRCP, FMedSci, FRS; and Gregg L. ­Semenza, MD, PhD for basic medical research; Ralf F.W. Bartenschlager, PhD; Charles M. Rice, PhD;...

issues in oncology

The Halifax Project: A New Approach to Combination Therapy

On August 13, 2013, more than 100 cancer researchers and physicians from around the world met in Halifax, Nova Scotia, Canada, to discuss 2 challenging problem areas in cancer. One group was focused on the carcinogenic potential of low-dose exposure to chemical mixtures in the environment, and the...

leukemia

Clinical Trials Actively Recruiting Patients With Acute Lymphoblastic Leukemia

Phase I Study Title: Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: Northwestern University, National...

Pioneer in Chemoradiation Robert B. Livingston, MD, Dies

Over the past couple of decades, chemoradiation for several cancers, such as lung and breast, has advanced in efficacy and side-effect tolerance, prolonging survival and quality of life for patients. One of the pioneers in chemoradiation, Robert B. Livingston, MD, died on September 8, 2016. Dr....

issues in oncology

Recognizing the Unique Experiences of Cancer Among Adolescent and Young Adult Survivors

Studies show that adolescent and young adult cancer survivors experience distinct challenges and quality-of-life issues from those experienced by either younger or older adult cancer survivors and that those challenges and issues can persist long after the cancer diagnosis and the end of...

leukemia

FDA Approves Blinatumomab for Use in Pediatric Patients With Ph-Negative Relapsed or Refractory B-Cell Precursor ALL

The U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome (Ph)-negative relapsed or refractory B-cell precursor acute...

Bassel El-Rayes, MD, to Hold John Kauffman Family Professorship at Winship

Bassel F. El-Rayes, MD, Associate Director of Clinical Research at Winship Cancer Institute of Emory University, was selected to hold the John Kauffman Family Professorship for Pancreatic Cancer Research. The new position was created to support an outstanding leader in the field of pancreatic...

Ainel Sewell, MD, to Lead Houston Methodist Breast Care Center

Ainel Sewell, MD, has been named the Medical Director of the Breast Care Center at Houston Methodist Willowbrook Hospital. Dr. Sewell is a board-certified radiologist specializing in breast imaging. “Being asked to lead the breast care center at Houston Methodist Willowbrook Hospital is an...

Jeff Allen, PhD, Named Friends’ First CEO

Friends of Cancer Research (Friends) has announced that its Executive Director, Jeff Allen, PhD, will assume the role of President and CEO of the organization. Friends’ founder, Ellen ­Sigal, PhD, will continue with the organization as Board Chair. Dr. Allen will become the day-to-day lead of...

Patricia LoRusso, DO, Named Chair of AACR’s Women in Cancer Research

Patricia LoRusso, DO, Professor of Medicine (Medical Oncology) and Associate Director of Innovative Medicine at Yale Cancer Center, has been named Chair of the Women in Cancer Research (WICR) Council of the American Association for Cancer Research (AACR). WICR is a membership group within the AACR ...

Researcher Spotlight: Conquering Cancer With Dr. Effinger

When it comes to pediatric cancer, there are so many signs of hope, starting with the fact that the childhood cancer 5-year survival rate has climbed all the way up to 83%. But while we celebrate the victories of all these children over cancer, little is known about the long-term health effects,...

ASCO and AAHPM Joint Statement Provides Guidance on Defining and Providing High-Quality Palliative Care

On August 16, the Journal of Oncology Practice (JOP) published a joint guidance statement from ASCO and the American Academy of Hospice and Palliative Medicine (AAHPM) regarding high-quality palliative care as delivered directly by medical oncology practices themselves.  ASCO has long recommended...

Cancer Survivorship Symposium Brings Together Oncologists and Primary Care Providers to Improve Patient Care

Significant advances in cancer care and treatment have led to a steady increase in survivorship—currently, more than 15.5 million cancer survivors are living in the United States. This number is only expected to grow, with an estimate of more than 20 million American cancer survivors in 2026.1 A...

Order Cancer.Net Fact Sheets for Your Practice

Be sure to check out Cancer.Net’s ASCO Answers fact sheets on a variety of topics, including tests and procedures, types of treatment, side effects, and more than 25 cancer types. These one-page (front and back) introductions include an overview, illustrations, terms to know, and questions to ask...

ASCO Members Advocate for Key Cancer Care Priorities at Home and on Capitol Hill

This summer, ASCO members continued their efforts to advocate for key issues that are critical to cancer care. ASCO members are uniquely qualified to communicate with Congress about effective policies for the treatment of patients with cancer and the research that drives scientific breakthroughs....

ASCO Continues Active Involvement in Cancer Moonshot

This summer, ASCO continued its active involvement in Vice President Joe Biden’s Cancer Moonshot Initiative. ASCO joined the Vice President at the formal launch of the moonshot earlier this year, and since then, has discussed research and policy proposals to advance discovery in cancer treatment...

Allison Aggon, DO, Joins Fox Chase Cancer Center

Allison Aggon, DO, has joined the Department of Surgical Oncology at Fox Chase Cancer Center, focusing on breast surgery. Dr. Aggon comes to Fox Chase from Crozer-Keystone Health System-Delaware County, where she has practiced as a breast surgeon and served as Medical Director of the Center for...

Stacey Ann Carter, MD, Joins Lester and Sue Smith Breast Center, Department of Surgery at Baylor

Stacey Ann Carter, MD, has joined the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine and the Department of Surgery as Assistant Professor. Dr. Carter joins the Breast Center team as a...

issues in oncology

Breaking the ‘Conspiracy of Silence’

A new study1 showing that just 1 in 20 terminally ill patients with cancer has sufficient understanding about the prognosis or purpose of treatment is highlighting the need for improvements in both the way oncologists communicate prognosis with their patients and in the development of educational...

Advertisement

Advertisement




Advertisement